BR112014012610A2 - método para tratar infecção causada pelo vírus da hepatite c utilizando composições contendo quercetina - Google Patents

método para tratar infecção causada pelo vírus da hepatite c utilizando composições contendo quercetina

Info

Publication number
BR112014012610A2
BR112014012610A2 BR112014012610A BR112014012610A BR112014012610A2 BR 112014012610 A2 BR112014012610 A2 BR 112014012610A2 BR 112014012610 A BR112014012610 A BR 112014012610A BR 112014012610 A BR112014012610 A BR 112014012610A BR 112014012610 A2 BR112014012610 A2 BR 112014012610A2
Authority
BR
Brazil
Prior art keywords
quercetin
virus infection
containing compositions
treating hepatitis
hepatitis
Prior art date
Application number
BR112014012610A
Other languages
English (en)
Inventor
Christian Lines Thomas
Original Assignee
Quercegen Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quercegen Pharmaceuticals Llc filed Critical Quercegen Pharmaceuticals Llc
Publication of BR112014012610A2 publication Critical patent/BR112014012610A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “método para tratar infecção causada pelo vírus da hepatite c utilizando composições contendo quercetina” um método para o tratamento de infecção causada pelo vírus da hepatite c com uma composição contendo quercetina, juntamente com um ou mais dentre vitamina b3, vitamina c, um composto folato. é também divulgado um método para o tratamento de condições associadas com um elevado nível de proteínas de choque térmico, incluindo câncer de fígado, usando a composição acima mencionada.
BR112014012610A 2011-11-23 2012-11-20 método para tratar infecção causada pelo vírus da hepatite c utilizando composições contendo quercetina BR112014012610A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/303,467 US20130129680A1 (en) 2011-11-23 2011-11-23 Method for treating hepatitis c virus infection using quercetin-containing compositions
PCT/US2012/066027 WO2013078184A2 (en) 2011-11-23 2012-11-20 Method for treating hepatitis c virus infection using quercetin-containing compositions

Publications (1)

Publication Number Publication Date
BR112014012610A2 true BR112014012610A2 (pt) 2017-06-06

Family

ID=48427178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012610A BR112014012610A2 (pt) 2011-11-23 2012-11-20 método para tratar infecção causada pelo vírus da hepatite c utilizando composições contendo quercetina

Country Status (14)

Country Link
US (1) US20130129680A1 (pt)
EP (1) EP2782578A4 (pt)
JP (1) JP2014533729A (pt)
KR (1) KR20140102227A (pt)
CN (1) CN104487074A (pt)
AU (1) AU2012340840B2 (pt)
BR (1) BR112014012610A2 (pt)
CA (1) CA2856506A1 (pt)
HK (1) HK1208364A1 (pt)
IN (1) IN2014MN00999A (pt)
MX (1) MX2014006244A (pt)
RU (1) RU2014125062A (pt)
WO (1) WO2013078184A2 (pt)
ZA (1) ZA201404494B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014354599A1 (en) * 2013-11-27 2016-06-09 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
WO2015196036A1 (en) * 2014-06-19 2015-12-23 Quercegen Pharmaceuticals Llc Method for treating cancer with a combination of quercetin and a chemotherapy agent
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
US10750758B2 (en) 2016-08-31 2020-08-25 Srikumar MISRA Curcumin infused milk beverage and a process for the preparation thereof
US10052293B2 (en) * 2016-08-31 2018-08-21 Srikumar MISRA Curcumin infused milk beverage and a process for the preparation thereof
CN107050011A (zh) * 2017-04-28 2017-08-18 灏ゅ己 染料木素在制备抗自身免疫性肝炎药物中的应用
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
RU2699932C1 (ru) * 2018-11-14 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ прогнозирования риска развития рака печени у экспериментальных животных
BR112021010500A2 (pt) 2018-11-30 2021-08-24 Beth Israel Deaconess Medical Center, Inc. Método para reduzir a p-selectina solúvel em um paciente com câncer, método para reduzir ou prevenir a formação de um trombo em um paciente com câncer, método para promover a regressão tumoral em um paciente com câncer, método para estabilizar ou reduzir o câncer metastático em um paciente com câncer, composição farmacêutica para reduzir a p-selectina solúvel em um paciente com câncer, composição farmacêutica para reduzir ou prevenir a formação de um trombo em um paciente com câncer, composição farmacêutica para promover a regressão tumoral em um paciente com câncer e composição farmacêutica para estabilizar ou reduzir câncer metastático em um paciente com câncer
US20220273686A1 (en) * 2019-08-06 2022-09-01 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Pharmaceutical composition for producing safe amount of nitric oxide and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
AU4463300A (en) * 1999-04-19 2000-11-02 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
WO2003030929A1 (en) * 2001-10-05 2003-04-17 Transition Therapeutics Inc. Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
US7560123B2 (en) * 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
CN100361599C (zh) * 2002-10-23 2008-01-16 克尔塞根控股有限公司 抗氧化组合物
CA2503363C (en) * 2002-10-23 2012-01-17 Quercegen Holdings Llc Antioxidative compositions
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
CN1822768A (zh) * 2003-06-13 2006-08-23 卡翁·Q·比伊 用于预防和治疗肝癌和肝病的营养药
US20070238793A1 (en) * 2005-12-07 2007-10-11 Lockwood Samuel F Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
JP5254227B2 (ja) * 2006-07-17 2013-08-07 クリスチャン ラインズ，トーマス ケルセチン含有組成物
WO2008011364A2 (en) * 2006-07-17 2008-01-24 Thomas Christian Lines Quercetin-containing compositions
WO2008095093A2 (en) * 2007-01-31 2008-08-07 Robert Keller Method of increasing cellular function and health of glutathione deficient animals
US8680053B2 (en) * 2008-07-09 2014-03-25 Quercegen Pharmaceuticals Llc Improving renal function with quercetin-containing compositions

Also Published As

Publication number Publication date
JP2014533729A (ja) 2014-12-15
CA2856506A1 (en) 2013-05-30
HK1208364A1 (en) 2016-03-04
EP2782578A4 (en) 2016-01-13
KR20140102227A (ko) 2014-08-21
MX2014006244A (es) 2015-03-03
US20130129680A1 (en) 2013-05-23
WO2013078184A2 (en) 2013-05-30
AU2012340840B2 (en) 2016-06-30
AU2012340840A1 (en) 2014-06-12
RU2014125062A (ru) 2015-12-27
NZ625746A (en) 2016-08-26
EP2782578A2 (en) 2014-10-01
CN104487074A (zh) 2015-04-01
ZA201404494B (en) 2016-01-27
IN2014MN00999A (pt) 2015-04-24

Similar Documents

Publication Publication Date Title
BR112014012610A2 (pt) método para tratar infecção causada pelo vírus da hepatite c utilizando composições contendo quercetina
BR112018067964A2 (pt) agentes antivirais para hepatite b
BR112018075465A2 (pt) agentes antivirais de hepatite b
PH12020550552A1 (en) Inhibitors of hepatitis c virus
EA201990495A1 (ru) Биарильные соединения, применимые в качестве иммуномодуляторов
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
BR112015021027A2 (pt) compostos terapêuticos
UY35300A (es) Formulación de combinación de dos compuestos antivirales
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201592184A1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
EA201691141A1 (ru) Соединения против ccr6
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
BR112015016325A2 (pt) Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo
EA201490846A1 (ru) Новые производные арилхинолина
BR112014013972A2 (pt) inibidores de hcv nssa
EA201391717A1 (ru) Ингибиторы вируса гепатита с
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
EA201590770A1 (ru) Ингибиторы вируса гепатита с
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.